This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing Information (PI), and Summary of Product Characteristics (SmPC) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.
The promotional events are intended for UK healthcare professionals experienced in the diagnosis and management of advanced Parkinson's disease only.
They have been organised and funded by AbbVie, including payment of speaker honoraria, and will contain information about Produodopa®
Date: Wednesday 10th June 2026
Time: 10:00–16:30
Location: Hilton London Metropole 225 Edgware Road, London, W2 1JU
Objectives:
- Share insights from nurses managing patients with advanced Parkinson’s disease, including the implementation of Produodopa® into clinical practice
- Discuss best practice and share practical experiences for the management of patients with advanced Parkinson’s disease, through case study-based discussions
- Provide skills-based training to support nurses to identify and present aPD patients for discussion at MDT
Date: Wednesday 10th June 2026
Time: 10:00–16:30
Location: Hilton London Metropole 225 Edgware Road, London, W2 1JU
Objectives:
- Share insights from nurses managing patients with advanced Parkinson’s disease, including the implementation of Produodopa® into clinical practice
- Discuss best practice and share practical experiences for the management of patients with advanced Parkinson’s disease, through case study-based discussions
- Provide skills-based training to support nurses to identify and present aPD patients for discussion at MDT
Accommodation is available on Tuesday 9 June 2026 for delegates travelling more than 2 hours to the venue, to ensure timely arrival.
Please note, your details will only be used for the purpose of communication for this meeting and will not be retained. Please email exploredPD@ashleycomms.com if you have any queries regarding this meeting.
Please refer to the PRODUODOPA SmPC for further information on adverse events, contraindications and special warnings and precautions for use.
References
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) Summary of Product Characteristics.
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-PRODD-260069. Date of preparation: March 2026.
